Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors
How Is the Urinary Retention Drug Market Growth Forecast from 2025 to 2029?
The urinary retention drug market size has grown strongly in recent years. It will grow from $3.87 billion in 2024 to $4.07 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to an increase in the aging population, increasing healthcare investments and improvements in medical infrastructure, a growing geriatric demographic, a rising geriatric population across the globe, and an increasing prevalence of BPH.
The urinary retention drug market size is expected to see strong growth in the next few years. It will grow to $5.1 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the increasing prevalence of urinary retention, rising incidence of postoperative urinary retention, increasing prevalence of urinary incontinence (UI), growing awareness about the benefits of early diagnosis and treatment, and increasing prevalence of benign prostatic hyperplasia. Major trends in the forecast period include targeted drug delivery systems, advances in drug formulations, artificial intelligence and machine learning, telemedicine and remote monitoring, and innovative solutions.
Claim your free report sample now:
Which Major Growth Factors Are Shaping the Urinary Retention Drug Market?
The rising prevalence of urinary disorders is expected to propel the growth of the urinary retention drug market going forward. Urinary disorders refer to conditions that affect the urinary system, causing issues such as difficulty urinating, pain, incontinence, or retention. The rising prevalence of urinary disorders is due to the increasing incidence of diabetes, as high blood sugar levels can damage the kidneys and urinary tract, leading to conditions such as diabetic nephropathy and frequent urinary tract infections. Urinary retention drugs help manage urinary disorders by improving urine flow, relaxing bladder muscles, and alleviating symptoms such as difficulty urinating, thereby enhancing comfort and bladder function. For instance, in October 2023, according to the National Health Service (NHS) England, a UK-based government department, hospitals recorded 147,285 admissions in 2022/23 with a primary diagnosis of urinary tract infection (UTI). Individuals aged over 65 accounted for 56% of these cases, totaling 82,392 admissions. The highest number of admissions occurred in the 80-84 age group, with 17,280 cases. Therefore, the rising prevalence of urinary disorders is driving the growth of urinary retention drug market.
Which Segment Offers the Highest Growth Opportunities in the Urinary Retention Drug Market?
The urinary retention drug market covered in this report is segmented –
1) By Drug Class: Alpha Blockers, Beta-3 Agonists, Anticholinergics, Surgical Agents
2) By Indication: Chronic Urinary Retention, Postoperative Urinary Retention, Neurogenic Bladder
3) By Administration: Oral, Injectable, Transdermal
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Alpha Blockers: Alpha-1 Blockers, Alpha-2 Blockers
2) By Beta-3 Agonists: Selective Beta-3 Agonists
3) By Anticholinergics: Antimuscarinics, Non-Selective Anticholinergics
4) By Surgical Agents: Anesthetics, Hemostatic Agents, Muscle Relaxants, Antibiotic Prophylaxis
What Are the Key Trends Shaping the Urinary Retention Drug Market?
Major companies in the urinary retention drug market are focusing on developing novel formulations such as extended-release tablets to improve patient compliance and provide prolonged symptom relief. Extended-release (ER) tablets are a type of medication formulation designed to release the active ingredient gradually over an extended period. This controlled-release mechanism maintains a consistent drug concentration in the bloodstream, reducing the frequency of dosing compared to immediate-release tablets. For instance, in April 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched a generic version of Mirabegron for overactive bladder (OAB). Mirabegron is a selective beta-3 adrenergic agonist that relaxes bladder muscles, reducing urinary urgency, frequency, and incontinence. While primarily used for OAB, it can also help manage urinary retention associated with overactive bladder conditions. The medication is administered as a once-daily oral dosage.
Who Are the Key Players Driving the Urinary Retention Drug Market?
Major companies operating in the urinary retention drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Ajanta Pharma Limited, Ferring Pharmaceuticals Inc., UroGen Pharma Ltd.
Get the full urinary retention drug market report here:
What Are the Regional Insights for the Urinary Retention Drug Market Forecast?
North America was the largest region in the urinary retention drug market in 2024. The regions covered in the urinary retention drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment